2,011 Shares in Johnson & Johnson (NYSE:JNJ) Acquired by Tallon Kerry Patrick

Tallon Kerry Patrick purchased a new position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 2,011 shares of the company's stock, valued at approximately $290,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Mirador Capital Partners LP boosted its holdings in shares of Johnson & Johnson by 5.5% in the fourth quarter. Mirador Capital Partners LP now owns 4,682 shares of the company's stock valued at $677,000 after acquiring an additional 245 shares during the period. IFS Advisors LLC boosted its stake in Johnson & Johnson by 138.9% during the 4th quarter. IFS Advisors LLC now owns 172 shares of the company's stock worth $25,000 after purchasing an additional 100 shares during the period. Hennion & Walsh Asset Management Inc. grew its position in Johnson & Johnson by 3.8% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 37,915 shares of the company's stock worth $5,483,000 after purchasing an additional 1,398 shares during the last quarter. Flywheel Private Wealth LLC acquired a new position in Johnson & Johnson in the fourth quarter valued at $514,000. Finally, Winch Advisory Services LLC boosted its stake in shares of Johnson & Johnson by 13.9% during the fourth quarter. Winch Advisory Services LLC now owns 3,316 shares of the company's stock worth $479,000 after buying an additional 404 shares during the period. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Price Performance

Johnson & Johnson stock traded down $0.74 during mid-day trading on Friday, reaching $147.03. The company had a trading volume of 10,678,393 shares, compared to its average volume of 6,880,262. The stock's 50-day simple moving average is $148.51 and its 200-day simple moving average is $155.96. The company has a market capitalization of $353.99 billion, a P/E ratio of 21.28, a P/E/G ratio of 2.30 and a beta of 0.51. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $168.85.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.21 by $0.21. The firm had revenue of $22.47 billion during the quarter, compared to analysts' expectations of $22.17 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. Johnson & Johnson's revenue was up 5.2% on a year-over-year basis. During the same period in the previous year, the firm posted $2.66 earnings per share. On average, equities analysts predict that Johnson & Johnson will post 9.94 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be paid a $1.24 dividend. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a yield of 3.37%. Johnson & Johnson's payout ratio is 71.78%.

Analysts Set New Price Targets

Several analysts have commented on JNJ shares. Wolfe Research began coverage on Johnson & Johnson in a research note on Friday, November 15th. They set an "outperform" rating and a $190.00 price objective for the company. Guggenheim upped their price target on Johnson & Johnson from $156.00 to $162.00 and gave the stock a "neutral" rating in a research note on Wednesday, November 6th. Citigroup lowered their price objective on shares of Johnson & Johnson from $185.00 to $175.00 and set a "buy" rating on the stock in a research report on Wednesday, December 11th. StockNews.com downgraded shares of Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research report on Friday. Finally, Royal Bank of Canada boosted their price target on shares of Johnson & Johnson from $178.00 to $181.00 and gave the stock an "outperform" rating in a research note on Wednesday, October 16th. Seven research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $174.29.

Insider Buying and Selling at Johnson & Johnson

In related news, Director Mark A. Weinberger purchased 1,000 shares of the company's stock in a transaction on Thursday, December 12th. The stock was bought at an average price of $147.22 per share, with a total value of $147,220.00. Following the completion of the transaction, the director now owns 1,000 shares of the company's stock, valued at approximately $147,220. This represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.